Arrowhead Pharmaceuticals, Inc.
ARWR
$55.05
$0.040.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 30.81M | -23.75M | -175.24M | 370.45M | -173.09M |
| Total Depreciation and Amortization | 6.39M | 6.39M | 6.22M | 6.08M | 5.24M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 38.07M | 76.22M | 32.26M | 38.00M | 29.02M |
| Change in Net Operating Assets | -61.79M | -38.36M | -17.96M | 45.53M | -7.44M |
| Cash from Operations | 13.48M | 20.49M | -154.72M | 460.05M | -146.27M |
| Capital Expenditure | -2.15M | -7.49M | -2.36M | -5.30M | -7.52M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -21.59M | 80.11M | 143.75M | -414.92M | 84.43M |
| Cash from Investing | -23.74M | 72.62M | 141.39M | -420.21M | 76.91M |
| Total Debt Issued | -- | 3.16M | 7.10M | -- | -- |
| Total Debt Repaid | -66.68M | 0.00 | -50.00M | -151.63M | -- |
| Issuance of Common Stock | 51.93M | 507.00K | 223.00K | 244.01M | 634.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | 0.00 | 20.00M |
| Cash from Financing | -14.75M | 3.67M | -42.68M | 92.38M | 20.63M |
| Foreign Exchange rate Adjustments | 106.00K | -24.00K | 93.00K | -402.00K | -68.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -24.91M | 96.76M | -55.92M | 131.82M | -48.80M |